These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6745307)

  • 21. Metronidazole and antipyrine metabolism in the rat: clearance determination from one saliva sample.
    Loft S; Nielsen AJ; Borg BE; Poulsen HE
    Xenobiotica; 1991 Jan; 21(1):33-46. PubMed ID: 2003365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ketoconazole does not impair antipyrine clearance in humans.
    Blyden GT; Abernethy DR; Greenblatt DJ
    Int J Clin Pharmacol Ther Toxicol; 1986 May; 24(5):225-6. PubMed ID: 3733272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interspecies scaling of the pharmacokinetic parameters of coumarin among six different mammalian species.
    Ritschel WA; Vachharajani NN; Johnson RD; Hussain AS
    Methods Find Exp Clin Pharmacol; 1991 Dec; 13(10):697-702. PubMed ID: 1770833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased values of antipyrine clearance in type IV hyperlipoproteinemia.
    Bedeleanu D; Trif I; Lötsch JC; Cucuianu MP
    Med Interne; 1986; 24(3):183-90. PubMed ID: 3775212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.
    Mahmood I; Balian JD
    Clin Pharmacokinet; 1999 Jan; 36(1):1-11. PubMed ID: 9989339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monthly variations in the pharmacokinetics of antipyrine in calves.
    Janus K; Baranow-Baranowski S; Jakubowska D; Jankowiak D; Skrzypczak WF
    Arch Vet Pol; 1992; 32(3-4):113-8. PubMed ID: 1339566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
    Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
    Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of cytochrome P-450 mediated metabolism of antipyrine in the rat at different extents of fluosol-DA hemodilution.
    Shrewsbury RP; White LG
    Res Commun Chem Pathol Pharmacol; 1990 Mar; 67(3):411-4. PubMed ID: 2343186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure.
    Carcillo JA; Doughty L; Kofos D; Frye RF; Kaplan SS; Sasser H; Burckart GJ
    Intensive Care Med; 2003 Jun; 29(6):980-984. PubMed ID: 12698250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
    Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
    Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anomalous results of studies on drug interaction in man. III. Disulfiram and antipyrine.
    Vesell ES; Passananti T; Glenwright PA
    Pharmacology; 1975; 13(6):481-91. PubMed ID: 1221431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interspecies scaling and comparisons in drug development and toxicokinetics.
    Ings RM
    Xenobiotica; 1990 Nov; 20(11):1201-31. PubMed ID: 2275215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig.
    van den Broek JM; Teunissen MW; Breimer DD
    Drug Metab Dispos; 1981; 9(6):541-4. PubMed ID: 6120813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic disposition of antipyrine in patients with lung cancer.
    Tschanz C; Hignite CE; Huffman DH; Azarnoff DL
    Cancer Res; 1977 Nov; 37(11):3881-6. PubMed ID: 908027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly.
    Engelking LR; Lofstedt J; Blyden GT; Greenblatt DJ
    Pharmacology; 1987; 34(4):192-200. PubMed ID: 3602088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of age on antipyrine metabolism in patients with gastric cancer.
    Higuchi T; Nakamura T; Uchino H
    J Natl Cancer Inst; 1980 Nov; 65(5):897-900. PubMed ID: 6933259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat.
    Adedoyin A; Aarons L; Houston JB
    Drug Metab Dispos; 1987; 15(1):127-32. PubMed ID: 2881749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of age on antipyrine pharmacokinetics and metabolite formation in rats.
    van Bezooijen CF; van Oorschot RM
    J Pharmacol Exp Ther; 1989 Nov; 251(2):683-6. PubMed ID: 2810117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.